Vaccine administrationWIKIMEDIA, US GOVERNMENT

The immunoglobulin G (IgG) antibody was key to the first-ever successful HIV vaccine trial in humans, reported researchers following up on the study's results.

In 2009, trial organizers announced that the particular vaccine combination used made people who received it 30 percent less likely to contract HIV than those who got a placebo. Since then, researchers have been pouring over blood samples from participants, hoping to determine the keys to the vaccine's marginal success where so many others have failed. Last week’s announcement marks one of the first answers to that question: individuals with the IgG antibody, which recognizes a specific part of HIV's envelope, were 43 percent less likely to contract the virus.

Knowing more about why the vaccine lent some protection against the virus may inform future efforts to create even more effective shots, perhaps targeting IgG production as a central strategy. "What...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?